On Monday, Eli Lilly and Co declared that it will allocate an extra $1.6 billion to its two new manufacturing sites located in Indiana, United States. This funding will facilitate the production of its
recently approved cancer drug, Jaypirca, among others. The total investment committed by the company in these facilities has now reached $3.7 billion.
Eli Lilly has made significant investments totaling $6.4 billion in enhancing its manufacturing capacity in the United States over the past three years. As the company prepares for the launch of new medications to treat obesity, Alzheimer's disease, and autoimmune disorders, it intends to further expand its production capabilities.
In January, the company had revealed plans to invest an additional $450 million to amplify the capacity of a plant located in North Carolina to meet the robust demand for its top-selling diabetes drug, Trulicity, and its recently launched medication, Mounjaro. The company's expansion commitments for the North Carolina site presently stand at $1.7 billion. Photo by Momoneymoproblemz, Wikimedia commons.